Search
Veracyte Inc
VCYTAdd to Watchlist
57.080USD
-2.770-4.63%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.53BMarket Cap
51.19P/E TTM
More Details of Veracyte Inc Company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Veracyte Inc Info
Ticker SymbolVCYT
Company nameVeracyte Inc
IPO dateOct 30, 2013
CEOStapley (Marc A)
Number of employees824
Security typeOrdinary Share
Fiscal year-endOct 30
Address6000 Shoreline Court, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502436300
Websitehttps://www.veracyte.com/
Ticker SymbolVCYT
IPO dateOct 30, 2013
CEOStapley (Marc A)
Company Executives of Veracyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
24.86K
-29.18%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
23.15K
+22.77%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
13.76K
-29.49%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
5.78K
+26.71%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%
FAQs
Who are the top five shareholders of Veracyte Inc?
The top five shareholders of Veracyte Inc are: Mr. Marc A. Stapley
How many institutions hold shares of Veracyte Inc (VCYT)?
As of 2026Q1, 683 institutions hold shares of Veracyte Inc, with a combined market value of approximately 96.10M, accounting for 120.44% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1894546.00.